Back to Journals » Drug Design, Development and Therapy » Volume 13

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis

Authors Yang EJ, Smith MP, Ly K, Bhutani T

Received 2 December 2018

Accepted for publication 25 February 2019

Published 18 June 2019 Volume 2019:13 Pages 1993—2000

DOI https://doi.org/10.2147/DDDT.S137588

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Cristiana Tanase


Eric J Yang,1,2 Mary Patricia Smith,1,3 Karen Ly,1,4 Tina Bhutani1

1Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA; 3Icahn School of Medicine at Mount Sinai, New York, NY, USA; 4School of Medicine, Wayne State University, Detroit, MI, USA

Abstract: The approval of guselkumab marks the entry of the IL-23 inhibitor class into the therapeutic armamentarium for patients with moderate-to-severe plaque psoriasis. This class specifically targets the upstream portion of the type 17 helper T (Th17) axis, which has been implicated as a key driver of the abnormal inflammatory state observed in psoriasis. Guselkumab is highly efficacious, with over 85% of the patients achieving ≥75% reduction in Psoriasis Area and Severity Index from baseline (PASI 75) and over 70% of the patients achieving PASI 90 response in its Phase III clinical trials. Additionally, this medication is well-tolerated, with non-serious infections such as nasopharyngitis and upper respiratory infections (URIs) being the most common adverse events (AEs) reported in its clinical trials. Guselkumab offers yet another effective treatment option in the rapidly growing list of available biological therapies for moderate-to-severe plaque psoriasis.

Keywords: biologics, guselkumab, IL-23 inhibitor, plaque psoriasis, biologic selection
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]